AbbVie's $950M Volume Drives 90th Market Rank Amid 310% Dividend Surge and Therapeutic Expansion

AbbVie (ABBV) closed on September 5, 2025, , , . , payable on November 14, 2025, to shareholders of record as of October 15. , maintaining its status in the S&P Dividend Aristocrats Index. The payout reflects AbbVie’s commitment to shareholder returns amid its focus on expanding therapeutic pipelines in immunology, oncology, and neuroscience.

Recent developments include the acquisition of Gilgamesh Pharmaceuticals’ depression treatment bretisilocin, . reiterated an Outperform rating, citing the drug’s novel mechanism in Phase 2 trials. Positive Phase 2 trial data for epcoritamab in lymphoma and upadacitinib in alopecia areata further highlight AbbVie’s progress in advancing its portfolio. These milestones underscore the company’s strategic emphasis on innovation across key therapeutic areas.

To run this back-test robustly I need to clarify a couple of practical details: 1. Universe definition • Should “top 500 stocks by daily trading volume” be drawn from a specific market (e.g., all U.S. listed equities), an index (e.g., S&P 500 constituents), or another universe? • If the universe can change over time, is it acceptable to re-select the top 500 every trading day based on that day’s volume (this is the usual interpretation)? 2. Data handling assumptions • Are we OK using the official consolidated-tape volume (total shares traded per day) with no survivorship-bias filters? • Any preference for handling corporate actions (splits, symbol changes) beyond the standard adjusted-price approach? 3. Trading-cost model • Should we assume zero costs/slippage, or apply a commission/spread estimate per trade? Once I know these points I can assemble the data-retrieval plan and run the back-test from 2022-01-03 (first U.S. trading day in 2022) through today.